Moderna has secured a European Commission contract to supply its RSV vaccine, mRESVIA, to six countries — Austria, Denmark, Ireland, Luxembourg, Norway, and Portugal. The deal covers up to 24 million doses over four years. The vaccine, delivered in a ready-to-use pre-filled syringe, is authorized in the EU to prevent lower respiratory tract disease caused by RSV in adults.
Moderna has inked a joint procurement deal with the European Commission to supply its mRNA-based RSV vaccine, mRESVIA, to six European countries: Austria, Denmark, Ireland, Luxembourg, Norway, and Portugal. The agreement mirrors a similar framework Moderna had with the EU for COVID-19 vaccines last year, signaling growing confidence in mRNA-based immunization strategies at the regional level.
mRESVIA will be delivered in a ready-to-use, single-dose pre-filled syringe — a format designed to simplify administration for healthcare professionals. The vaccine is authorized in the EU to prevent lower respiratory tract disease caused by RSV in adults, a virus that is a leading cause of pneumonia and death in both infants and older adults.
By the Numbers:
Why it matters: This deal expands access to RSV protection across Europe through a coordinated procurement approach, reinforcing the EU's strategy of collective vaccine purchasing — and further cementing Moderna's position as a key player in the mRNA respiratory vaccine market.
